top of page

NCI-2023-03139

Updated: Feb 21

A Study of PARG Inhibitor IDE161 in Participants with Advanced Solid Tumors


This study is investigating the use of a new medicine called IDE161 in participants with advanced solid tumors. The main purpose of the study is to evaluate the safety and efficacy of IDE161 in this patient population. The researchers aim to assess how well IDE161 works in shrinking tumors and whether it has manageable side effects.


For more information about the trial, click the link below:

Clinical Trial Site: Columbia


To see all available clinical trials click here.



 
 
 

Recent Posts

See All
NCI-2025-06021

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer (TRIPL) This is a research study exploring how combining radiation therapy with dual immune check

 
 
 
NCI-2024-05588

A Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT) The INSI

 
 
 
NCI-2022-08569

Randomized Phase III Trial of mFOLFIRINOX /- Nivolumab vs. FOLFOX /- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma This randomized Phase III research

 
 
 

Comments

bottom of page